NOL12

Across TCGA pan-cancer cohorts, NOL12 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NOL12 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher NOL12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NOL12 expression acts as an unfavorable survival marker.

LUSC, ESCA, and PRAD are the cancer types where NOL12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	30	view →
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	OS	Median	All	0.167	0.688	.035	6	view →
SKCM	DFS	Median	All	0.235	0.613	.044	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NOL12–LUSC (DFS)

Open the LUSC breakdown →